View ValuationThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsOtonomy 将来の成長Future 基準チェック /06主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長14.6%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報Price Target Changed • Nov 16Price target increased to US$9.00Up from US$6.00, the current price target is provided by 1 analyst. New target price is 6,823% above last closing price of US$0.13. Stock is down 94% over the past year. The company is forecast to post a net loss per share of US$0.77 next year compared to a net loss per share of US$0.81 last year.Price Target Changed • Aug 02Price target decreased to US$5.83Down from US$6.63, the current price target is an average from 4 analysts. New target price is 2,240% above last closing price of US$0.25. Stock is down 85% over the past year. The company is forecast to post a net loss per share of US$0.72 next year compared to a net loss per share of US$0.81 last year.Price Target Changed • Apr 27Price target increased to US$6.50Up from US$5.90, the current price target is an average from 5 analysts. New target price is 191% above last closing price of US$2.23. Stock is down 9.7% over the past year. The company is forecast to post a net loss per share of US$0.77 next year compared to a net loss per share of US$0.81 last year.Price Target Changed • Apr 21Price target increased to US$6.50Up from US$5.90, the current price target is an average from 5 analysts. New target price is 190% above last closing price of US$2.24. Stock is down 2.6% over the past year. The company is forecast to post a net loss per share of US$0.77 next year compared to a net loss per share of US$0.81 last year.Major Estimate Revision • Aug 11Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$183.8k to US$158.3k. EPS estimate increased from -US$0.81 to -US$0.78 per share. Pharmaceuticals industry in the US expected to see average net income growth of 14% next year. Consensus price target of US$6.30 unchanged from last update. Share price fell 5.5% to US$1.56 over the past week.Major Estimate Revision • May 18Consensus revenue estimates increase to US$183.8kThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$118.8k to US$183.8k. Forecast losses expected to reduce from -US$0.87 to -US$0.81 per share. Pharmaceuticals industry in the US expected to see average net income growth of 13% next year. Consensus price target of US$6.30 unchanged from last update. Share price rose 15% to US$2.37 over the past week.すべての更新を表示Recent updatesお知らせ • Feb 18Otonomy, Inc. Announces Executive ChangesOn February 15, 2023, the board of directors of the Otonomy, Inc. appointed H. Michael Hogan, a representative of Armanino LLP (Armanino), a consultant to the Company, to the Board. In connection and simultaneously with Mr. Hogan’s appointment to the Board, the size of the Board was reduced to one and Jay Lichter, Ph.D., James B. Breitmeyer, M.D., Ph.D., Jill Broadfoot, Vickie Capps, Ciara Kennedy, Ph.D., Iain McGill, Theodore R. Schroeder and David A. Weber, Ph.D. resigned from the Board. The directors did not resign because of any disagreement with the Company relating to its operations, policies or practices. Mr. Hogan will serve as a director pursuant to the Company’s engagement of Armanino, but will not receive any compensation for his service as the Company’s sole director.Price Target Changed • Nov 16Price target increased to US$9.00Up from US$6.00, the current price target is provided by 1 analyst. New target price is 6,823% above last closing price of US$0.13. Stock is down 94% over the past year. The company is forecast to post a net loss per share of US$0.77 next year compared to a net loss per share of US$0.81 last year.Price Target Changed • Aug 02Price target decreased to US$5.83Down from US$6.63, the current price target is an average from 4 analysts. New target price is 2,240% above last closing price of US$0.25. Stock is down 85% over the past year. The company is forecast to post a net loss per share of US$0.72 next year compared to a net loss per share of US$0.81 last year.Seeking Alpha • Aug 01Otonomy crashes 73% as mid-stage trial for tinnitus candidate failsThe shares of neurology focused Otonomy (NASDAQ:OTIC) plunged ~73% in the pre-market Monday after the company said its Phase 2 trial for OTO-313 did not demonstrate a clinically meaningful benefit for OTO-313 compared to placebo in hearing disorder tinnitus. "These results were unexpected with a much higher placebo response than observed in the prior Phase 1/2 study,” Chief Executive David A. Weber noted, adding that the company would discontinue further development of OTO-313 and take other steps to extend cash runway. This is a developing story. Check back for more updates.Seeking Alpha • Jul 25Otonomy GAAP EPS of -$0.19 beats by $0.01Otonomy press release (NASDAQ:OTIC): Q2 GAAP EPS of -$0.19 beats by $0.01. Cash Position: Cash, cash equivalents, and short-term investments totaled $53.1 million as of June 30, 2022, compared to $77.4 million as of December 31, 2021. Outlook: Financial Guidance: Otonomy expects that GAAP operating expenses for 2022 will be in the range of $52-$54 million, and that non-GAAP operating expenses will be in the range of $42-$44 million.Reported Earnings • May 10First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.23 loss in 1Q 2021)First quarter 2022 results: US$0.20 loss per share. Net loss: US$13.6m (loss widened 11% from 1Q 2021). Over the next year, revenue is expected to shrink by 100% compared to a 6.9% growth forecast for the industry in the US.Price Target Changed • Apr 27Price target increased to US$6.50Up from US$5.90, the current price target is an average from 5 analysts. New target price is 191% above last closing price of US$2.23. Stock is down 9.7% over the past year. The company is forecast to post a net loss per share of US$0.77 next year compared to a net loss per share of US$0.81 last year.Price Target Changed • Apr 21Price target increased to US$6.50Up from US$5.90, the current price target is an average from 5 analysts. New target price is 190% above last closing price of US$2.24. Stock is down 2.6% over the past year. The company is forecast to post a net loss per share of US$0.77 next year compared to a net loss per share of US$0.81 last year.Seeking Alpha • Apr 04Otonomy: Hearing Loss And Tinnitus Data In 2022Data for OTO-413 in hearing loss is due early in Q2 2002. Data for OTO-313 in tinnitus is due mid-2022. Tinnitus and hearing loss are indications with no FDA-approved medicines and are each billion-dollar markets. Precedent suggests developing therapeutics for these indications is an extremely difficult task.Reported Earnings • Mar 03Full year 2021 earnings: EPS exceeds analyst expectationsFull year 2021 results: US$0.81 loss per share (up from US$1.10 loss in FY 2020). Net loss: US$51.2m (loss widened 14% from FY 2020). Products in clinical trials Phase II: 2 Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.5%. Over the next year, revenue is expected to shrink by 100% compared to a 20% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 12Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.22 loss in 3Q 2020)Third quarter 2021 results: Net loss: US$12.9m (loss widened 19% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.Major Estimate Revision • Aug 11Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$183.8k to US$158.3k. EPS estimate increased from -US$0.81 to -US$0.78 per share. Pharmaceuticals industry in the US expected to see average net income growth of 14% next year. Consensus price target of US$6.30 unchanged from last update. Share price fell 5.5% to US$1.56 over the past week.Reported Earnings • Aug 06Second quarter 2021 earnings released: US$0.19 loss per share (vs US$0.37 loss in 2Q 2020)Second quarter 2021 results: Net loss: US$12.5m (loss widened 9.2% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.分析記事 • Jun 16Shareholders Will Probably Hold Off On Increasing Otonomy, Inc.'s (NASDAQ:OTIC) CEO Compensation For The Time BeingShareholders of Otonomy, Inc. ( NASDAQ:OTIC ) will have been dismayed by the negative share price return over the last...Major Estimate Revision • May 18Consensus revenue estimates increase to US$183.8kThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$118.8k to US$183.8k. Forecast losses expected to reduce from -US$0.87 to -US$0.81 per share. Pharmaceuticals industry in the US expected to see average net income growth of 13% next year. Consensus price target of US$6.30 unchanged from last update. Share price rose 15% to US$2.37 over the past week.Reported Earnings • May 13First quarter 2021 earnings released: US$0.23 loss per share (vs US$0.38 loss in 1Q 2020)First quarter 2021 results: Net loss: US$12.2m (loss widened 3.8% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.Major Estimate Revision • Apr 14Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 losses forecast to reduce from -US$1.09 to -US$0.87 per share. Revenue forecast unchanged from US$118.8k at last update. Pharmaceuticals industry in the US expected to see average net income growth of 16% next year. Consensus price target up from US$5.91 to US$6.10. Share price fell 16% to US$2.17 over the past week.Is New 90 Day High Low • Feb 23New 90-day low: US$3.00The company is down 31% from its price of US$4.37 on 24 November 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$101 per share.Major Estimate Revision • Feb 18Analysts lower revenue estimates to US$91.7kThe 2021 consensus revenue estimate decreased from US$7.56m. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -US$1.01 to -US$1.06 for the same period. The Pharmaceuticals industry in the US is expected to see an average net income growth of 14% next year. The consensus price target of US$10.80 was unchanged from the last update. Share price is up 5.2% to US$5.63 over the past week.Analyst Estimate Surprise Post Earnings • Feb 13Revenue and earnings miss expectationsRevenue missed analyst estimates by 48%. Earnings per share (EPS) also missed analyst estimates by 5.6%. Over the next year, revenue is forecast to grow 2,669%, compared to a 31% growth forecast for the Pharmaceuticals industry in the US.Reported Earnings • Feb 13Full year 2020 earnings released: US$1.10 loss per share (vs US$1.45 loss in FY 2019)Full year 2020 results: Net loss: US$44.7m (flat on FY 2019). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.分析記事 • Feb 02Is Otonomy (NASDAQ:OTIC) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Price Target Changed • Dec 19Price target raised to US$10.80Up from US$9.40, the current price target is an average from 5 analysts. The new target price is 69% above the current share price of US$6.38. As of last close, the stock is up 158% over the past year.Is New 90 Day High Low • Dec 18New 90-day high: US$5.98The company is up 51% from its price of US$3.95 on 18 September 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$149 per share.分析記事 • Dec 11Are Institutions Heavily Invested In Otonomy, Inc.'s (NASDAQ:OTIC) Shares?A look at the shareholders of Otonomy, Inc. ( NASDAQ:OTIC ) can tell us which group is most powerful. Institutions will...Is New 90 Day High Low • Dec 02New 90-day high: US$4.79The company is up 29% from its price of US$3.70 on 02 September 2020. The American market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$125 per share.Analyst Estimate Surprise Post Earnings • Nov 07Revenue and earnings miss expectationsRevenue missed analyst estimates by 9.1%. Earnings per share (EPS) also missed analyst estimates by 9.6%. Over the next year, revenue is forecast to grow 1,756%, compared to a 30% growth forecast for the Pharmaceuticals industry in the US.Reported Earnings • Nov 07Third quarter 2020 earnings released: US$0.22 loss per shareThird quarter 2020 results: Net loss: US$10.9m (loss widened 8.2% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Oct 03New 90-day high: US$4.44The company is up 41% from its price of US$3.16 on 02 July 2020. The American market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$117 per share. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Otonomy は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:OTIC - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/2022N/A-52-47-47N/A6/30/2022N/A-53-45-44N/A3/31/20220-53-45-44N/A12/31/20210-51-43-42N/A9/30/20210-48-41-41N/A6/30/20210-46-41-41N/A3/31/20210-45-39-39N/A12/31/20200-45-39-39N/A9/30/20200-45-38-38N/A6/30/20200-44-38-38N/A3/31/20201-44-39-39N/A12/31/20191-45-38-37N/A9/30/20191-47-40-40N/A6/30/20191-49-38-38N/A3/31/20191-51-40-39N/A12/31/20181-50-39-38N/A9/30/20181-56-43-42N/A6/30/20181-65-51-50N/A3/31/20181-74-58-57N/A12/31/20171-90-77-75N/A9/30/20171-98-81-79N/A6/30/20171-104-89-86N/A3/31/20171-111-98-95N/A12/31/20161-111-97-94N/A9/30/20160-105-93-90N/A6/30/20160-94N/A-80N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: OTICの予測収益成長が 貯蓄率 ( 2.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: OTICの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: OTICの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: OTICの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: OTICの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: OTICの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/04/13 20:23終値2023/04/11 00:00収益2022/09/30年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Otonomy, Inc. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Aaron GalBernsteinSumant Satchidanand KulkarniBofA Global ResearchCharles DuncanCantor Fitzgerald & Co.6 その他のアナリストを表示
Price Target Changed • Nov 16Price target increased to US$9.00Up from US$6.00, the current price target is provided by 1 analyst. New target price is 6,823% above last closing price of US$0.13. Stock is down 94% over the past year. The company is forecast to post a net loss per share of US$0.77 next year compared to a net loss per share of US$0.81 last year.
Price Target Changed • Aug 02Price target decreased to US$5.83Down from US$6.63, the current price target is an average from 4 analysts. New target price is 2,240% above last closing price of US$0.25. Stock is down 85% over the past year. The company is forecast to post a net loss per share of US$0.72 next year compared to a net loss per share of US$0.81 last year.
Price Target Changed • Apr 27Price target increased to US$6.50Up from US$5.90, the current price target is an average from 5 analysts. New target price is 191% above last closing price of US$2.23. Stock is down 9.7% over the past year. The company is forecast to post a net loss per share of US$0.77 next year compared to a net loss per share of US$0.81 last year.
Price Target Changed • Apr 21Price target increased to US$6.50Up from US$5.90, the current price target is an average from 5 analysts. New target price is 190% above last closing price of US$2.24. Stock is down 2.6% over the past year. The company is forecast to post a net loss per share of US$0.77 next year compared to a net loss per share of US$0.81 last year.
Major Estimate Revision • Aug 11Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$183.8k to US$158.3k. EPS estimate increased from -US$0.81 to -US$0.78 per share. Pharmaceuticals industry in the US expected to see average net income growth of 14% next year. Consensus price target of US$6.30 unchanged from last update. Share price fell 5.5% to US$1.56 over the past week.
Major Estimate Revision • May 18Consensus revenue estimates increase to US$183.8kThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$118.8k to US$183.8k. Forecast losses expected to reduce from -US$0.87 to -US$0.81 per share. Pharmaceuticals industry in the US expected to see average net income growth of 13% next year. Consensus price target of US$6.30 unchanged from last update. Share price rose 15% to US$2.37 over the past week.
お知らせ • Feb 18Otonomy, Inc. Announces Executive ChangesOn February 15, 2023, the board of directors of the Otonomy, Inc. appointed H. Michael Hogan, a representative of Armanino LLP (Armanino), a consultant to the Company, to the Board. In connection and simultaneously with Mr. Hogan’s appointment to the Board, the size of the Board was reduced to one and Jay Lichter, Ph.D., James B. Breitmeyer, M.D., Ph.D., Jill Broadfoot, Vickie Capps, Ciara Kennedy, Ph.D., Iain McGill, Theodore R. Schroeder and David A. Weber, Ph.D. resigned from the Board. The directors did not resign because of any disagreement with the Company relating to its operations, policies or practices. Mr. Hogan will serve as a director pursuant to the Company’s engagement of Armanino, but will not receive any compensation for his service as the Company’s sole director.
Price Target Changed • Nov 16Price target increased to US$9.00Up from US$6.00, the current price target is provided by 1 analyst. New target price is 6,823% above last closing price of US$0.13. Stock is down 94% over the past year. The company is forecast to post a net loss per share of US$0.77 next year compared to a net loss per share of US$0.81 last year.
Price Target Changed • Aug 02Price target decreased to US$5.83Down from US$6.63, the current price target is an average from 4 analysts. New target price is 2,240% above last closing price of US$0.25. Stock is down 85% over the past year. The company is forecast to post a net loss per share of US$0.72 next year compared to a net loss per share of US$0.81 last year.
Seeking Alpha • Aug 01Otonomy crashes 73% as mid-stage trial for tinnitus candidate failsThe shares of neurology focused Otonomy (NASDAQ:OTIC) plunged ~73% in the pre-market Monday after the company said its Phase 2 trial for OTO-313 did not demonstrate a clinically meaningful benefit for OTO-313 compared to placebo in hearing disorder tinnitus. "These results were unexpected with a much higher placebo response than observed in the prior Phase 1/2 study,” Chief Executive David A. Weber noted, adding that the company would discontinue further development of OTO-313 and take other steps to extend cash runway. This is a developing story. Check back for more updates.
Seeking Alpha • Jul 25Otonomy GAAP EPS of -$0.19 beats by $0.01Otonomy press release (NASDAQ:OTIC): Q2 GAAP EPS of -$0.19 beats by $0.01. Cash Position: Cash, cash equivalents, and short-term investments totaled $53.1 million as of June 30, 2022, compared to $77.4 million as of December 31, 2021. Outlook: Financial Guidance: Otonomy expects that GAAP operating expenses for 2022 will be in the range of $52-$54 million, and that non-GAAP operating expenses will be in the range of $42-$44 million.
Reported Earnings • May 10First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.23 loss in 1Q 2021)First quarter 2022 results: US$0.20 loss per share. Net loss: US$13.6m (loss widened 11% from 1Q 2021). Over the next year, revenue is expected to shrink by 100% compared to a 6.9% growth forecast for the industry in the US.
Price Target Changed • Apr 27Price target increased to US$6.50Up from US$5.90, the current price target is an average from 5 analysts. New target price is 191% above last closing price of US$2.23. Stock is down 9.7% over the past year. The company is forecast to post a net loss per share of US$0.77 next year compared to a net loss per share of US$0.81 last year.
Price Target Changed • Apr 21Price target increased to US$6.50Up from US$5.90, the current price target is an average from 5 analysts. New target price is 190% above last closing price of US$2.24. Stock is down 2.6% over the past year. The company is forecast to post a net loss per share of US$0.77 next year compared to a net loss per share of US$0.81 last year.
Seeking Alpha • Apr 04Otonomy: Hearing Loss And Tinnitus Data In 2022Data for OTO-413 in hearing loss is due early in Q2 2002. Data for OTO-313 in tinnitus is due mid-2022. Tinnitus and hearing loss are indications with no FDA-approved medicines and are each billion-dollar markets. Precedent suggests developing therapeutics for these indications is an extremely difficult task.
Reported Earnings • Mar 03Full year 2021 earnings: EPS exceeds analyst expectationsFull year 2021 results: US$0.81 loss per share (up from US$1.10 loss in FY 2020). Net loss: US$51.2m (loss widened 14% from FY 2020). Products in clinical trials Phase II: 2 Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.5%. Over the next year, revenue is expected to shrink by 100% compared to a 20% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 12Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.22 loss in 3Q 2020)Third quarter 2021 results: Net loss: US$12.9m (loss widened 19% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
Major Estimate Revision • Aug 11Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$183.8k to US$158.3k. EPS estimate increased from -US$0.81 to -US$0.78 per share. Pharmaceuticals industry in the US expected to see average net income growth of 14% next year. Consensus price target of US$6.30 unchanged from last update. Share price fell 5.5% to US$1.56 over the past week.
Reported Earnings • Aug 06Second quarter 2021 earnings released: US$0.19 loss per share (vs US$0.37 loss in 2Q 2020)Second quarter 2021 results: Net loss: US$12.5m (loss widened 9.2% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
分析記事 • Jun 16Shareholders Will Probably Hold Off On Increasing Otonomy, Inc.'s (NASDAQ:OTIC) CEO Compensation For The Time BeingShareholders of Otonomy, Inc. ( NASDAQ:OTIC ) will have been dismayed by the negative share price return over the last...
Major Estimate Revision • May 18Consensus revenue estimates increase to US$183.8kThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$118.8k to US$183.8k. Forecast losses expected to reduce from -US$0.87 to -US$0.81 per share. Pharmaceuticals industry in the US expected to see average net income growth of 13% next year. Consensus price target of US$6.30 unchanged from last update. Share price rose 15% to US$2.37 over the past week.
Reported Earnings • May 13First quarter 2021 earnings released: US$0.23 loss per share (vs US$0.38 loss in 1Q 2020)First quarter 2021 results: Net loss: US$12.2m (loss widened 3.8% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
Major Estimate Revision • Apr 14Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 losses forecast to reduce from -US$1.09 to -US$0.87 per share. Revenue forecast unchanged from US$118.8k at last update. Pharmaceuticals industry in the US expected to see average net income growth of 16% next year. Consensus price target up from US$5.91 to US$6.10. Share price fell 16% to US$2.17 over the past week.
Is New 90 Day High Low • Feb 23New 90-day low: US$3.00The company is down 31% from its price of US$4.37 on 24 November 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$101 per share.
Major Estimate Revision • Feb 18Analysts lower revenue estimates to US$91.7kThe 2021 consensus revenue estimate decreased from US$7.56m. Earnings per share (EPS) also decreased, with analysts lowering their estimates from -US$1.01 to -US$1.06 for the same period. The Pharmaceuticals industry in the US is expected to see an average net income growth of 14% next year. The consensus price target of US$10.80 was unchanged from the last update. Share price is up 5.2% to US$5.63 over the past week.
Analyst Estimate Surprise Post Earnings • Feb 13Revenue and earnings miss expectationsRevenue missed analyst estimates by 48%. Earnings per share (EPS) also missed analyst estimates by 5.6%. Over the next year, revenue is forecast to grow 2,669%, compared to a 31% growth forecast for the Pharmaceuticals industry in the US.
Reported Earnings • Feb 13Full year 2020 earnings released: US$1.10 loss per share (vs US$1.45 loss in FY 2019)Full year 2020 results: Net loss: US$44.7m (flat on FY 2019). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
分析記事 • Feb 02Is Otonomy (NASDAQ:OTIC) Using Debt In A Risky Way?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Price Target Changed • Dec 19Price target raised to US$10.80Up from US$9.40, the current price target is an average from 5 analysts. The new target price is 69% above the current share price of US$6.38. As of last close, the stock is up 158% over the past year.
Is New 90 Day High Low • Dec 18New 90-day high: US$5.98The company is up 51% from its price of US$3.95 on 18 September 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$149 per share.
分析記事 • Dec 11Are Institutions Heavily Invested In Otonomy, Inc.'s (NASDAQ:OTIC) Shares?A look at the shareholders of Otonomy, Inc. ( NASDAQ:OTIC ) can tell us which group is most powerful. Institutions will...
Is New 90 Day High Low • Dec 02New 90-day high: US$4.79The company is up 29% from its price of US$3.70 on 02 September 2020. The American market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$125 per share.
Analyst Estimate Surprise Post Earnings • Nov 07Revenue and earnings miss expectationsRevenue missed analyst estimates by 9.1%. Earnings per share (EPS) also missed analyst estimates by 9.6%. Over the next year, revenue is forecast to grow 1,756%, compared to a 30% growth forecast for the Pharmaceuticals industry in the US.
Reported Earnings • Nov 07Third quarter 2020 earnings released: US$0.22 loss per shareThird quarter 2020 results: Net loss: US$10.9m (loss widened 8.2% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Oct 03New 90-day high: US$4.44The company is up 41% from its price of US$3.16 on 02 July 2020. The American market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$117 per share.